Physician profile
Ryan C Headley
NPI 1659309375
$23,992.65
in general payments reported to CMS, 2019-2025
36 companies · $93.26 in 2025
The $93.26 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,153 · 2020: $12K · 2021: $6,058 · 2022: $2,499 · 2023: $569 · 2024: $894 · 2025: $93.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $12,786.32 | 2019-2020 | |
| Medtronic, INC. | $6,704.34 | 2021-2025 | Maxtack, Ligasure |
| Intuitive Surgical, INC. | $1,722.50 | 2019-2025 | Da Vinci Surgical System |
| Takeda Pharmaceuticals U.S.A., INC. | $324.46 | 2020-2024 | Gattex, Eohilia |
| Aimmune Therapeutics, INC. | $289.56 | 2024 | |
| Novo Nordisk INC | $286.73 | 2019-2025 | Wegovy |
| Davol INC. | $247.39 | 2019-2021 | |
| Ethicon US, LLC | $178.07 | 2019-2023 | Echelon Flex |
| Myriad Genetic Laboratories, INC. | $166.66 | 2023 | Myrisk |
| Smith+Nephew, INC. | $161.89 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $152.58 | 2020-2024 | Gore Enform Preperitoneal Biomaterial, Gore Synecor Biomaterial |
| Pacira Pharmaceuticals Incorporated | $110.41 | 2019-2024 | Exparel |
| Centinel Spine, LLC | $104.17 | 2023 | Prodisc L |
| Teleflex LLC | $68.72 | 2022-2024 | Titan Sgs |
| Tela Bio, INC. | $68.71 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $64.13 | 2019-2021 | |
| Integra Lifesciences Corporation | $56.21 | 2021 | |
| Shire North American Group INC | $55.88 | 2019 | |
| Polynovo North America LLC | $47.82 | 2024 | Novosorb Btm |
| Innovation Technologies INC | $43.44 | 2019-2023 | Irrisept |
| Boston Scientific Corporation | $39.72 | 2024 | Spyglass Discover |
| Hologic Sales and Service, LLC | $31.34 | 2022 | |
| Acera Surgical, INC. | $27.23 | 2019 | |
| Braintree Laboratories, INC. | $25.66 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $23.82 | 2023 | Clenpiq |
| Osiris Therapeutics INC. | $23.67 | 2019 | |
| Sirius Medical Systems | $23.07 | 2024 | Pintuition |
| Tei Biosciences INC | $22.03 | 2019 | |
| Endo Pharmaceuticals INC. | $20.33 | 2020 | |
| Lilly USA, LLC | $18.15 | 2024 | Jardiance, Zepbound |
| Baxter Healthcare | $17.81 | 2022 | |
| Kerecis Limited | $17.64 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Thd America, INC. | $17.60 | 2023 | |
| Conmed Corporation | $16.44 | 2021 | |
| Becton, Dickinson and Company | $14.22 | 2019 | |
| Echosens North America, INC. | $13.93 | 2023 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Headley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.